<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830397</url>
  </required_header>
  <id_info>
    <org_study_id>QC-201</org_study_id>
    <nct_id>NCT04830397</nct_id>
  </id_info>
  <brief_title>Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).</brief_title>
  <official_title>A Randomized Active-controlled Multi-site Double-masked Study to Evaluate the Safety and Tolerability of 3 Concentrations of QLS-101 Versus Timolol Maleate Preservative Free (PF) 0.5% Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qlaris Bio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qlaris Bio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution&#xD;
      in glaucoma or ocular hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-site study to evaluate the safety and tolerability of 3 concentrations of QLS-101&#xD;
      versus timolol maleate Preservative Free (PF) 0.5% ophthalmic solution in subjects with&#xD;
      primary open-angle glaucoma or ocular hypertension&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular safety</measure>
    <time_frame>100 days</time_frame>
    <description>Number of participants with treatment-related adverse events will be monitored</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular hypotensive efficacy</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants with intraocular pressure reduction from baseline will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>QLS-101 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QLS-101 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>QLS-101 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol Maleate 0.5% preservative free ophthalmic solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLS-101</intervention_name>
    <description>Ophthalmic solution 1x daily</description>
    <arm_group_label>QLS-101 0.5%</arm_group_label>
    <arm_group_label>QLS-101 1%</arm_group_label>
    <arm_group_label>QLS-101 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol Maleate</intervention_name>
    <description>Ophthalmic solution 1x daily</description>
    <arm_group_label>Timolol Maleate 0.5% preservative free ophthalmic solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Visual acuity +1.0 logMAR or better&#xD;
&#xD;
          2. Willing to give informed consent&#xD;
&#xD;
          3. Ability to washout from current intraocular pressure lowering medications -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe glaucomatous damage&#xD;
&#xD;
          2. Previous glaucoma intraocular or laser surgery&#xD;
&#xD;
          3. Refractive surgery&#xD;
&#xD;
          4. Ocular infection or inflammation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cheryl St John</last_name>
    <phone>508-514-9034</phone>
    <email>cstjohn@qlaris.bio</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Brandano</last_name>
    <phone>978-930-2103</phone>
    <email>lbrandano@qlaris.bio</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dixon Eye Care</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://qlaris.bio/pipeline</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elevated intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

